Cryopreserved Pre-embryo Transfer in a Cytokine-rich Medium Versus Hyaluronic Acid (CSF-EG)
Transferencia de Preembriones Criopreservados en un Medio Rico en Citoquinas Versus ácido hialurónico: Estudio clínico Aleatorizado
This multicenter, randomized, double-blind study compares a GM-CSF-enriched embryo transfer medium with a hyaluronic acid-enriched medium in women undergoing single frozen embryo transfer. It will assess whether the GM-CSF medium is non-inferior for clinical pregnancy rates. Participants will be randomly assigned to one of the two groups.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Hyaluronic acid is commonly used in embryo transfer media to support embryo-endometrial adhesion. GM-CSF is a cytokine that may help regulate cellular stress and apoptosis after embryo warming. This study will compare a GM-CSF-supplemented transfer medium with a hyaluronic acid-supplemented medium in frozen embryo transfer cycles. Its primary aim is to determine whether the GM-CSF medium is non-inferior to the hyaluronic acid medium for clinical pregnancy. The results may help inform the choice of transfer medium in assisted reproduction.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Nicolás Prados Dodd
- Telefonnummer: +34 954 28 62 74
- E-mail: vida.investiga@gruporecoletas.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women aged 18 to 50 years.
- Undergoing transfer of a single cryopreserved embryo (SET) from own and/or donor gametes.
Exclusion Criteria:
- Uterine malformations or conditions that, in the physician's judgment, could affect implantation.
- Transfer of more than one embryo.
- Transfer of mosaic embryos.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: GM-CSF-supplemented transfer medium
Participants receive a single frozen embryo transfer using SAGE 1-Step medium with GM-CSF. |
Embryo transfer medium enriched with cytokines, used for the transfer of cryopreserved embryos. |
|
Aktiv komparator: Hyaluronic acid-enriched transfer medium
Participants receive a single frozen embryo transfer using EmbryoGlue medium enriched with hyaluronic acid. |
Embryo transfer medium enriched with hyaluronic acid, used for the transfer of cryopreserved embryos. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical pregnancy rate per embryo transfer
Tidsramme: 6-9 weeks of gestation after embryo transfer.
|
Proportion of embryo transfers resulting in an intrauterine gestational sac and fetal heartbeat confirmed by ultrasound. |
6-9 weeks of gestation after embryo transfer.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Biochemical pregnancy rate per embryo transfer
Tidsramme: 9-15 days after embryo transfer.
|
Proportion of participants with a positive serum β-hCG test after embryo transfer. |
9-15 days after embryo transfer.
|
|
Ongoing pregnancy rate per embryo transfer
Tidsramme: 6-9 weeks of gestation after embryo transfer.
|
Proportion of participants with embryonic heartbeat detected. |
6-9 weeks of gestation after embryo transfer.
|
|
Live birth rate per embryo transfer
Tidsramme: From embryo transfer through delivery, up to 9 months after embryo transfer.
|
Proportion of participants with a live-born infant at delivery. |
From embryo transfer through delivery, up to 9 months after embryo transfer.
|
|
Biochemical pregnancy loss rate per embryo transfer
Tidsramme: From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.
|
Pregnancy loss after a positive or indeterminate β-hCG result, without ultrasound confirmation of a gestational sac. |
From serum β-hCG testing at 9-15 days after embryo transfer through ultrasound assessment at 6-9 weeks of gestation.
|
|
Clinical pregnancy loss rate per embryo transfer
Tidsramme: After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.
|
Pregnancy loss after an intrauterine gestational sac has been confirmed. |
After ultrasound confirmation of the gestational sac; the protocol does not specify a final follow-up time point.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2601_VAL_MA
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared with other researchers. Study results will be disseminated through publications and presentations in aggregate form.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .